Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25145643 | 1.00 | HCRTR2 (0.33) | HCRTR2HCRTR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25290150 | 0.86 | HCRTR2 (0.34) | HCRTR2HCRTR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21607008 | 0.81 | HRH1 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31307995 | 0.80 | HCRTR2 (0.35) | HCRTR2HCRTR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31239631 | 0.78 | HCRTR1 (0.33) | HCRTR2HCRTR1ALOX5APFEN1 | |
| SCHEMBL25145541 | 0.78 | HCRTR1 (0.33) | HCRTR2HCRTR1ALOX5APFEN1 | |
| SCHEMBL31532572 | 0.78 | SLC6A4 (0.38) | HCRTR2HCRTR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25253196 | 0.78 | LOXL2 (0.38) | HCRTR2HCRTR1 | |
| SCHEMBL25145627 | 0.74 | MALT1 (0.44) | ALOX5APFEN1 | |
| SCHEMBL25412091 | 0.74 | SCN9A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-119301113-A | Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118103374-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | HCRTR2 87/4885HCRTR1 41/4885SLC6A2 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.